Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 5 de 5
Filtrar
1.
Mol Genet Metab ; 133(1): 35-48, 2021 05.
Artigo em Inglês | MEDLINE | ID: mdl-33736941

RESUMO

Autosomal hereditary recessive diseases characterized by genetic instability are often associated with cancer predisposition. Bloom syndrome (BS), a rare genetic disorder, with <300 cases reported worldwide, combines both. Indeed, patients with Bloom's syndrome are 150 to 300 times more likely to develop cancers than normal individuals. The wide spectrum of cancers developed by BS patients suggests that early initial events occur in BS cells which may also be involved in the initiation of carcinogenesis in the general population and these may be common to several cancers. BS is caused by mutations of both copies of the BLM gene, encoding the RecQ BLM helicase. This review discusses the different aspects of BS and the different cellular functions of BLM in genome surveillance and maintenance through its major roles during DNA replication, repair, and transcription. BLM's activities are essential for the stabilization of centromeric, telomeric and ribosomal DNA sequences, and the regulation of innate immunity. One of the key objectives of this work is to establish a link between BLM functions and the main clinical phenotypes observed in BS patients, as well as to shed new light on the correlation between the genetic instability and diseases such as immunodeficiency and cancer. The different potential implications of the BLM helicase in the tumorigenic process and the use of BLM as new potential target in the field of cancer treatment are also debated.


Assuntos
Síndrome de Bloom/genética , Neoplasias/genética , RecQ Helicases/genética , Síndrome de Bloom/complicações , Síndrome de Bloom/patologia , Replicação do DNA/genética , Instabilidade Genômica , Humanos , Mutação/genética , Neoplasias/complicações , Neoplasias/patologia , Ligação Proteica/genética
2.
Gene ; 782: 145533, 2021 May 25.
Artigo em Inglês | MEDLINE | ID: mdl-33636291

RESUMO

BACKGROUND: Human papillomavirus is the most common sexually transmitted infection. It is associated with different cancers, mainly cervical cancer, which remains the fourth most frequent cancer among women worldwide; it is also related to anogenital (anus, vulvar, vagina, and penis) and oropharyngeal cancers. Vaccination against HPV infection is the major way of prevention, and it has demonstrated impressive efficacy in reducing cervical cancer incidence. Nowadays, all the licensed HPV recombinant vaccines were designed based on HPV major capsid L1 protein. However, some variations in the HPV L1 gene sequence may induce structural changes within the L1 protein, which may alter the affinity and interaction of monoclonal antibodies (MAbs) with L1 protein epitopes, and influence host immune response and recognition. Hence, the importance of accuracy in delineating epitopes relevant to vaccine design and defining genetic variations within antigenic regions in the L1 gene to predict its impact on prophylactic vaccine efficiency. The present review reports the sequence variations in HR-HPV L1 gene isolates from different countries around the world, which may help to understand the effect of HPV L1 gene variations on vaccine efficiency. METHODS: Research studies were retrieved from PubMed, Google Scholar, Science direct, and the National Center for Biotechnology Information (NCBI) database. A total of 31 articles describing genetic variations within the major capsid L1 gene and conducted in Africa, Europe, America and Asia were found. Only 26 studies conducted on HPV16, 18, 31, 33, 58, 45 and 52 which are the targets of HPV prophylactic vaccines, and which reported genetic variations within the L1 gene, were selected and evaluated in this review. FINDINGS: We found a total of 87, 49, 11, 7, 22, 3, and 17 non-synonymous single nucleotide polymorphisms (SNPs) within HPV16, HPV18, HPV31, HPV58, HPV45, and HPV52 L1 gene, respectively. Four mutations were frequently observed in HPV16 L1 sequences: T353P in the HI loop, H228D in the EF loop, T266A in the FG loop, and T292A in the FG loop. Two mutations in HPV58 L1 sequences: T375N in the HI loop and L150F in the DE loop. Three mutations in HPV33 L1 sequences: T56N in the BC loop, G133S in the DE loop, T266K in the FG loop. Other mutations were found in HPV18, HPV45, and HPV52 L1 sequences. Some were found in different countries, and others were specific to a given population. Furthermore, some variations were located on peptide binding epitopes and lead to a modification of epitopes, which may influence MAbs interactions. Others need further investigations due to the lack of studies. CONCLUSION: This study investigated the major capsid L1 genetic diversity of HPV16, 18, 31, 33, 58, 45, and 52 circulating in different populations around the world. Further investigations should be conducted to confirm their effect on immunogenicity and prophylactic vaccine efficiency.


Assuntos
Proteínas do Capsídeo/genética , Variação Genética , Proteínas Oncogênicas Virais/genética , Papillomaviridae/genética , Vacinas contra Papillomavirus/imunologia , Animais , Anticorpos Antivirais/imunologia , Afinidade de Anticorpos , Proteínas do Capsídeo/imunologia , Saúde Global , Humanos , Imunogenicidade da Vacina/genética , Proteínas Oncogênicas Virais/imunologia , Papillomaviridae/fisiologia , Vacinas contra Papillomavirus/genética
3.
Afr Health Sci ; 20(4): 1849-1856, 2020 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-34394248

RESUMO

BACKGROUND: The incidence of thyroid cancer is increasing worldwide at an alarming rate. BRAFV600E mutation is described to be associated with a worse prognostic of thyroid carcinomas, as well as extrathyroidal invasion and increased mortality. OBJECTIVE: To our knowledge, there are no reported studies neither from Morocco nor from other Maghreb countries regarding the prevalence of BRAFV600E mutation in thyroid carcinomas. Here we aim to evaluate the frequency of BRAFV600E oncogene in Moroccan thyroid carcinomas. METHODS: In this Single-Institution retrospective study realized in the Anatomic Pathology and Histology Service in the Military Hospital of Instruction Mohammed V 'HMIMV' in Rabat, we report, using direct genomic sequencing, the assessment of BRAFV600E in 37 thyroid tumors. RESULTS: We detected BRAFV600E mutation exclusively in Papillary Thyroid Carcinomas 'PTC' with a prevalence of 28% (8 PTC out 29 PTC). Like international trends, Papillary Thyroid Carcinomas 'PTC' is more frequent than Follicular Thyroid Carcinomas 'FTC' and Anaplastic Thyroid Carcinomas 'ATC' (29 PTC, 7 FTC and 1 ATC). CONCLUSION: Our finding gives to the international community the first estimated incidence of this oncogene in Morocco showing that this prevalence falls within the range of international trends (30% to 90%) reported in distinct worldwide geographic regions.


Assuntos
Proteínas Proto-Oncogênicas B-raf/genética , Neoplasias da Glândula Tireoide/genética , Adenocarcinoma Folicular/genética , Adulto , Carcinoma Papilar, Variante Folicular/genética , Análise Mutacional de DNA , DNA de Neoplasias/análise , Feminino , Humanos , Incidência , Masculino , Pessoa de Meia-Idade , Marrocos/epidemiologia , Mutação , Mutação Puntual , Polimorfismo de Fragmento de Restrição , Prevalência , Proteínas Proto-Oncogênicas B-raf/metabolismo , Estudos Retrospectivos , Câncer Papilífero da Tireoide , Neoplasias da Glândula Tireoide/etnologia , Neoplasias da Glândula Tireoide/patologia
4.
Cell Cycle ; 1(4): 262-6, 2002.
Artigo em Inglês | MEDLINE | ID: mdl-12429945

RESUMO

Patients with Bloom's syndrome (BS) show a strong genetic instability and a predisposition to all types of cancer. Here, we report that the Bloom's syndrome protein (BLM) is cleaved in response to hydroxyurea (HU)- or UVC-induced apoptosis. The appearance and solubility of BLM proteolytic products differed according to whether proteolysis occurred in response to HU or UVC. One BS cell line homozygous for a null mutation in BLM was resistant to both UVC- and HU-induced apoptosis, while another one expressing a mutated BLM protein was resistant to HU-induced apoptosis but displayed normal sensitivity to UVC. Thus, UVC and HU appear to induce apoptosis through distinct pathways.


Assuntos
Adenosina Trifosfatases/metabolismo , Antineoplásicos/farmacologia , Apoptose , Síndrome de Bloom/tratamento farmacológico , Síndrome de Bloom/radioterapia , DNA Helicases/metabolismo , Hidroxiureia/farmacologia , Raios Ultravioleta , Adenosina Trifosfatases/química , Terapia Combinada , DNA Helicases/química , Genes p53/genética , Humanos , Imuno-Histoquímica , Células K562 , RecQ Helicases , Fatores de Tempo , Células Tumorais Cultivadas
5.
Oncogene ; 21(13): 2079-88, 2002 Mar 27.
Artigo em Inglês | MEDLINE | ID: mdl-11960380

RESUMO

Bloom's syndrome (BS) arises through mutations in both copies of the BLM gene that encodes a RecQ 3'-5' DNA helicase. BS patients are predisposed to developing all the cancers that affect the general population, and BS cells exhibit marked genetic instability. We showed recently that BLM protein contributes to the cellular response to ionizing radiation by acting as downstream ATM kinase effector. We now show that following UVC treatment, BLM-deficient cells exhibit a reduction in the number of replicative cells, a partial escape from the G2/M cell cycle checkpoint, and have an altered p21 response. Surprisingly, we found that hydroxyurea-treated BLM-deficient cells exhibit an intact S phase arrest, proper recovery from the S phase arrest, and intact p53 and p21 responses. We also show that the level of BLM falls sharply in response to UVC radiation. This UVC-induced reduction in BLM does not require a functional ATM gene and does not result from a subcellular compartment change. Finally, we demonstrate that exposure to UVC and hydroxyurea treatment both induce BLM phosphorylation via an ATM-independent pathway. These results are discussed in the light of their potential physiological significance with regard to the role of BLM in the cellular pathways activated by UVC radiation or HU-mediated inhibition of DNA synthesis.


Assuntos
Adenosina Trifosfatases/metabolismo , DNA Helicases/metabolismo , Replicação do DNA/efeitos dos fármacos , Replicação do DNA/efeitos da radiação , DNA/efeitos dos fármacos , Hidroxiureia/farmacologia , Raios Ultravioleta , Adenosina Trifosfatases/deficiência , Adenosina Trifosfatases/genética , Proteínas Mutadas de Ataxia Telangiectasia , Síndrome de Bloom/genética , Proteínas de Ciclo Celular , Divisão Celular/efeitos dos fármacos , Divisão Celular/efeitos da radiação , Inibidor de Quinase Dependente de Ciclina p21 , Ciclinas/metabolismo , DNA/biossíntese , DNA Helicases/deficiência , DNA Helicases/genética , Proteínas de Ligação a DNA , Citometria de Fluxo , Fase G2/efeitos dos fármacos , Fase G2/efeitos da radiação , Regulação da Expressão Gênica/efeitos da radiação , Humanos , Mitose/efeitos dos fármacos , Mitose/efeitos da radiação , Fosforilação/efeitos dos fármacos , Proteínas Serina-Treonina Quinases/metabolismo , RecQ Helicases , Fase S/efeitos dos fármacos , Fase S/efeitos da radiação , Fatores de Tempo , Células Tumorais Cultivadas , Proteína Supressora de Tumor p53/metabolismo , Proteínas Supressoras de Tumor
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA